Roche subsidiary Genentech on Wednesday released data from the Phase III OCARINA II study, showing that its investigational subcutaneous formulation for Ocrevus (ocrelizumab) strongly reduced relapses and brain lesions in patients with relapsing or primary progressive multiple sclerosis.
Tag Archive for: Ocrevus
Moving forward, Roche is prioritizing and reimagining its R&D strategy to build a stronger portfolio.
Data from the OCARINA II trial shows that a 10-minute subcutaneous injection of Ocrevus achieves similar pharmacokinetics as the typical hours-long intravenous infusion in multiple sclerosis patients.
TG Therapeutics Inc. said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up 47% in afternoon trade.
A strong product pipeline and increased group sales confirm that Roche is on the right growth path.
